Rgenta Therapeutics, Inc.
Small molecule drugs that lower HTT protein levels through RNA-targeting mechanism for Huntington's disease treatment
- Sector
- Biotech
- Headquarters
- MA
- Founded
- 2019
- Latest Form D
- $8.9M, Feb 2022
- Total capital
- $15.3M
- Federal grants
- $400K
- 1 award · 2020
- Rank in peer group#337 of 502
- Private capital raised
- $14.9M
- 2 Form D · last Feb 2022
- 57 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 21 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$8.9M
- Federal grantHealth and Human S · Phase I · Discover HTT-lowering small-molecule drugs to treat Huntington's disease$400K
- Private capital raisedForm D · SEC · 1st filing$6M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 502 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Travis Simon WagerResearcherExecutive OfficerLinked by $400K in grants as PI
- Debasish Simon RoychowdhuryDirectorNamed in SEC Form D filings
- Fei ShenDirectorNamed in SEC Form D filings
- Hongbo Simon LuDirectorNamed in SEC Form D filings
- Hualin Simon XiExecutive Officer, DirectorNamed in SEC Form D filings
- Hualin Simon XiExecutive Officer, DirectorNamed in SEC Form D filings
Show all 10 people
- Judith Simon LiDirectorNamed in SEC Form D filings
- Martin Simon HeideckerDirectorNamed in SEC Form D filings
- Sun LinghaoDirectorNamed in SEC Form D filings
- Zhiping WengDirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 21- Pending5-PYRIMIDINECARBOXAMIDE Derivatives And Methods Of Using The SameUSPTOApplication 18714624
- PendingHeterocyclic Amides And Methods Of Using The SameUSPTOApplication 18710312
- PendingHeterocyclic Substituted 1,3,4-THIADIAZOLE And Pyridazine Compounds And Methods Of Using The SameUSPTOApplication 18711986
Show all 21 patent records
- 5-PYRIMIDINECARBOXAMIDE Derivatives And Methods Of Using The SameApr 17, 2025 · Application 18714624Pending
- Heterocyclic Amides And Methods Of Using The SameFeb 27, 2025 · Application 18710312Pending
- Heterocyclic Substituted 1,3,4-THIADIAZOLE And Pyridazine Compounds And Methods Of Using The SameFeb 6, 2025 · Application 18711986Pending
- Fused Triazinone Derivatives And Methods Of Using The SameJan 23, 2025 · Application 18708108Pending
- Methods Of Using Fused TriazinonesApplication PCTUS2024029691Pending
- Small-molecule Regulated Alternative SplicingApplication PCTUS2024024522Pending
- 2,3-DIHYDROPYROLLOPYRIDINE Carboxamide Compounds And Methods Of Use ThereofApplication 63601947Pending
- Methods Of Using Fused TriazinonesApplication 63467266Pending
- Small-molecule Regulated Alternative SplicingApplication 63496199Pending
- 5-PYRIMIDINECARBOXAMIDE Derivatives And Methods Of Using The SameApplication PCTUS2022051722Pending
- Heterocyclic Substituted 1,3,4-THIADIAZOLE And Pyridazine Compounds And Methods Of Using The SameApplication PCTUS2022080352Pending
- Heterocyclic Amides And Methods Of Using The SameApplication PCTUS2022080182Pending
- Fused Triazinone Derivatives And Methods Of Using The SameApplication PCTUS2022079748Pending
- 5-PYRIMIDINECARBOXAMIDE Derivatives And Methods Of Using The SameApplication 63285629Pending
- Heterocyclic Substituted 1,3,4-THIADIAZOLE And Pyridazine Compounds And Methods Of Using The SameApplication 63281988Pending
- Heterocyclic Amides And Methods Of Using The SameApplication 63280939Pending
- Small-molecule Regulated Alternative SplicingApplication 63708070Pending
- Fused Triazinone Derivatives And Methods Of Using The SameApplication 63278726Pending
- Small-molecule Regulated Alternative SplicingApplication PCTUS2025051076Pending
- Small-molecule Regulated Alternative SplicingApplication 19475291Pending
- 2,3-DIHYDROPYROLLOPYRIDINE Carboxamide Compounds And Methods Of Use ThereofApplication PCTUS2024057078Pending
Related companies, and why
- SEMBA BIOSCIENCES, INC.Similar federal contract value in Biotech · null in contracts
- Expansion Technologies, Inc.Similar federal contract value in Biotech · null in contracts
- Peel Therapeutics, IncSimilar federal contract value in Biotech · null in contracts
- REVEL PHARMACEUTICALS INC.Similar federal contract value in Biotech · null in contracts
- ADRX, INC.Similar federal contract value in Biotech · null in contracts
- TRANSCODE THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .